118th Congress · HOUSE BILLBILL

H.R. 6897 — Synthetic Biology and Active Pharmaceutical Ingredients Act

“To require the Secretary of Defense to establish a pilot program to evaluate novel pharmaceutical manufacturing technologies to reduce the reliance of the Department on foreign manufacturers for active pharmaceutical ingredients and key starting materials.”

Health

Introduced Dec 22, 2023

Last action Dec 22, 2023

Pipeline · Bill → Law

Step 1

Introduced

Dec 22, 2023

Step 2

Referred

Dec 22, 2023

Armed Services

Step 3

Committee

Step 4

House floor

Step 5

Senate

Step 6

Resolve Changes

Step 7

Signed

SummaryCRS Summary

This bill requires the Department of Defense (DOD) to establish a pilot program to support domestic manufacturing of critical pharmaceutical ingredients and their components through certain novel technology. Specifically, DOD must establish a three-year program that uses technology involving synthetic biology to support domestic manufacturing of pharmaceutical ingredients and related incorporated materials that (1) are not available in a sufficient quantity or quality domestically, and (2) are strategically important to the United States.

Provisions · 1 sectionsIntroduced in House

Timeline · 2 actions

Dec 22, 2023

Introduced in House

Dec 22, 2023

Referred to the House Committee on Armed Services.